Parent Project Muscular Dystrophy
8
1M
7
3
0.12
2
- Areas of investment
Summary
Among the most successful fund investment fields, there are Medical, Health Care. Among the most popular portfolio startups of the fund, we may highlight Tivorsan Pharmaceuticals, Prosensa. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
The typical case for the fund is to invest in rounds with 1 participant. Despite the Parent Project Muscular Dystrophy, startups are often financed by Idinvest Partners, Gimv, Prosensa.
The increased amount of exits for fund were in 2013. Deals in the range of 100 thousands - 1 million dollars are the general things for fund. The high activity for fund was in 2012. The fund is generally included in less than 2 deals every year.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 3
- Exits
- 2
- Follow on index
- 0.12
- Investments by industry
- Biotechnology (5)
- Therapeutics (4)
- Health Care (3)
- Pharmaceutical (2)
- Medical (1) Show 11 more
- Investments by region
-
- United States (6)
- Canada (1)
- Netherlands (1)
- Peak activity year
- 2022
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 47
- Avg. valuation at time of investment
- 120M
- Group Appearance index
- 0.12
- Avg. company exit year
- 8
- Avg. multiplicator
- 8.51
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Myosana Therapeutics | 07 Dec 2022 | Biotechnology, Therapeutics | Seed | 5M | United States, Washington, Seattle |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.